Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | SPX-303 |
Synonyms | |
Therapy Description |
Limited information is currently available on SPX-303, a putative bispecific antibody targeting LILRB2 and CD274 (PD-L1) (Feb 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SPX-303 | SPX303|SPX 303 | PD-L1/PD-1 antibody 117 | Limited information is currently available on SPX-303, a putative bispecific antibody targeting LILRB2 and CD274 (PD-L1) (Feb 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06259552 | Phase I | SPX-303 | A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors (SPX-303) | Recruiting | USA | 0 |